Who Paid My Doc
Christopher Hugge
Pediatric Hematology-Oncology St. Louis, MO Medical Doctor
NPI 1235140328 CMS profile 540495
1465 S Grand Blvd, St. Louis, MO 63104
General payments
$185
Research payments
$0
Ownership & investment interest
$0
Through program year 2023, Christopher Hugge of St. Louis, MO is reported in the CMS Open Payments database as having received $185 across 2 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 32nd percentile of Pediatric Hematology-Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
2 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2023 | General | $121 | 1 | |
| 2019 | General | $64 | 1 |
Beside peers
- Christopher Hugge
- Pediatric Hematology-Oncology median
- Middle half of Pediatric Hematology-Oncology
- National median
In program year 2025, general payments to Christopher Hugge were reported at $0. Among 1,352 Pediatric Hematology-Oncology profiles paid that year, the median was $204 and the middle half received between $80 and $2,819.
Show as a table
| Year | Christopher Hugge | Pediatric Hematology-Oncology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $64 | $184 | $69–$2,094 | $163 |
| 2020 | $0 | $220 | $37–$3,941 | $114 |
| 2021 | $0 | $366 | $63–$4,909 | $132 |
| 2022 | $0 | $181 | $66–$2,775 | $149 |
| 2023 | $121 | $175 | $62–$2,600 | $160 |
| 2024 | $0 | $227 | $66–$2,992 | $164 |
| 2025 | $0 | $204 | $80–$2,819 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 2 drugsPart D claims
44
Drug cost
$397
Branded share of claims
36.4%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Morphine Sulfate Er Morphine Sulfate | Brand | 16 | $286 | |
| Oxycodone Hcl | Generic | 28 | $111 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 8,746 Part D prescribers listed as Hematology-Oncology; they describe a distribution and say nothing about conduct.
Records
2 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Pediatric Hematology-Oncology in Missouri
Michael Silvey
Pediatric Hematology-Oncology · Kansas City, MO
Lauren Amos
Pediatric Hematology-Oncology · Kansas City, MO
Ibrahim Ahmed
Pediatric Hematology-Oncology · Kansas City, MO
Mohamed Abdelbaki
Pediatric Hematology-Oncology · Saint Louis, MO
Amy Armstrong
Pediatric Hematology-Oncology · Saint Louis, MO
Melanie Fields
Pediatric Hematology-Oncology · Saint Louis, MO
Related records
Pediatric Hematology-Oncology in Missouri
Practitioners in the same specialty and state, ranked by reported value.
All Pediatric Hematology-Oncology
Everyone recorded under this specialty, nationwide.
Doctors in Missouri
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.